论文部分内容阅读
我院血研所1997年1月至1999年10月试用HA方案并基因重组α-2b干扰素(rhJFNa-2b,商品名安达芬Anterfer-on,系安徽安可生物高技术有限责任公司产品)治疗初治的慢性粒细胞性白血病(CML),取得较满意的疗效,现总结分析如下。1 临床资料1.1 病例选择 本组9例均系住院的初治病人,男7例,女2例;年龄10～62岁。本组9例经临床血、骨髓象、染色体检查均符合CML的诊断,ph染色体均阳性。1.2 治疗方法1.2.1 HA方案(标准剂量)联合化疗,H(高三尖杉酯碱)3～4mg/d以5％葡萄糖液250ml稀释静脉滴注1次,Ara-c(阿糖胞苷)200～300mg/d,隔12h肌肉注射100～150mg,连续7d为1个疗程,间歇7d再行第2疗程;儿童病例按体重计算给药。
The Institute of Blood Research in our hospital used the HA program from January 1997 to October 1999 and genetically reconstitutes α-2b interferon (rhJFNa-2b, trade name Anderfer-on, an Anhui Anke Bio-Technology Co., Ltd. product) The treatment of newly diagnosed chronic myelogenous leukemia (CML) has achieved satisfactory results. The summary analysis is as follows. 1 Clinical data 1.1 Case selection This group of 9 cases were all hospitalized initial treatment patients, 7 males and 2 females; aged 10 to 62 years old. Nine patients in this group were diagnosed with CML by clinical blood, bone marrow, and chromosomes, and their ph chromosomes were positive. 1.2 Treatment 1.2.1 HA (standard dose) combined with chemotherapy, H (Homoharringtonine) 3 ~ 4mg / d 5% glucose solution 250ml diluted intravenous infusion of Ara-c (Ara-C) 200 ~ 300mg / d, intramuscular injection of 100 ~ 150mg every 12h, 7d for a course of treatment, interval 7d and then the second course of treatment; child cases were calculated according to body weight administration.